GlassScriptPhysician profile
Andrew Athmer
NPI 1982951166
$899.81
in general payments reported to CMS, 2019-2025
11 companies · $607 in 2025
The $607 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.60 · 2022: $57.98 · 2023: $122 · 2024: $99.73 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $828.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $280.73 | 2024-2025 | |
| Boston Scientific Corporation | $142.73 | 2025 | General - Vascular Intervention |
| Abiomed | $137.48 | 2025 | |
| Novo Nordisk INC | $121.86 | 2023 | |
| Medtronic, INC. | $49.92 | 2025 | Corevalve Evolut R |
| Janssen Pharmaceuticals, INC | $48.79 | 2021-2024 | Xarelto |
| Abbott Laboratories | $38.61 | 2025 | Cardiomems |
| Ultragenyx Pharmaceutical INC. | $23.26 | 2022 | |
| Phathom Pharmaceuticals, INC. | $21.71 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $17.81 | 2022 | |
| Dynavax Technologies Corporation | $16.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Athmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.